Abstract
The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
CNS & Neurological Disorders - Drug Targets
Title: Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence
Volume: 7 Issue: 5
Author(s): Christian Heidbreder
Affiliation:
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
Abstract: The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Export Options
About this article
Cite this article as:
Heidbreder Christian, Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927822
DOI https://dx.doi.org/10.2174/187152708786927822 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Predicting Drug-Likeness: Why and How ?
Current Topics in Medicinal Chemistry Monoclonal Antibodies: A Review
Current Clinical Pharmacology Editorial [ Hot Topic:Magic Bullets and Arrows: Biologic Approaches to Treat Substance Use Disorders (Guest Editor: Phil Skolnick and Nora D. Volkow)]
CNS & Neurological Disorders - Drug Targets Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers
Current Medicinal Chemistry Editorial (Thematic Issue: Small and Supramolecular Chemistry in Drug Design, Drug Discovery and Drug Delivery)
Current Topics in Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery S100b Induces Expression of Myoglobin in APβ Treated Neuronal Cells In Vitro: A Possible Neuroprotective Mechanism
Current Aging Science Hydromorphone: Analytical Methodologies for its Determination
Current Analytical Chemistry Microarray Data Analysis: Current Practices and Future Directions
Current Pharmacogenomics <i>In-silico</i> Studies and Biological Activity of Potential BACE-1 Inhibitors
Combinatorial Chemistry & High Throughput Screening Understanding the Structural Basis of ALDH-2 Inhibition by Molecular Docking
Medicinal Chemistry Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Hypopituitarism in the Elderly: Multifaceted Clinical and Biochemical Presentation
Current Aging Science A Review of Premature Frailty in HIV-Infected Persons; Another Manifestation of HIV-Related Accelerated Aging
Current Aging Science The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies
Current Pharmaceutical Design